Literature DB >> 7860407

Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma.

K Sakai1, H Inakoshi, H Sueyama, J Oda, T Ito, E Tsuchida, T Sugita, Y Matsumoto, M Saito, A Saito.   

Abstract

PURPOSE: The feasibility of a concurrent chemoradiotherapeutic protocol for patients with inoperable esophageal squamous cell carcinoma was tested. METHODS AND MATERIALS: Concurrent chemoradiotherapy using protracted low-dose continuous infusions of five-fluorouracil (5-FU; 250-300 mg/m2/24 h) and standard external beam irradiation was given to 28 patients with inoperable esophageal squamous cell carcinoma between November 1991 and June 1993.
RESULTS: For 25 patients receiving a total dose of > or = 60 Gy and concurrent 5-FU infusion for more than 5 weeks, the complete response rate was 52%. Local progression-free rate in this chemoradiotherapy group was significantly higher than the historical controls treated by radiotherapy alone (p < 0.05). A multivariate analysis revealed the treatment scheme (concomitant chemoradiotherapy vs. radiotherapy alone) to be a significant factor in local control (p < 0.01). Swallowing pain (39%), anorexia (39%), and nausea (32%) were the most frequent early reactions. Serious late radiation complications have not been observed.
CONCLUSION: The concurrent chemoradiotherapy using protracted low-dose continuous infusion of 5-FU and standard radiotherapy is an effective and safe method to obtain a local control in inoperable esophageal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7860407     DOI: 10.1016/0360-3016(94)00415-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Yasumasa Nishimura; Keiichi Jingu; Satoshi Itasaka; Yoshiharu Negoro; Yuji Murakami; Katsuyuki Karasawa; Gen Kawaguchi; Fumiaki Isohashi; Masao Kobayashi; Yoshiyuki Itoh; Takuro Ariga
Journal:  Int J Clin Oncol       Date:  2015-07-16       Impact factor: 3.402

2.  Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.

Authors:  Bryan H Burmeister; Euan T Walpole; Elizabeth A Burmeister; Janine Thomas; Damien B Thomson; Jennifer A Harvey; B Mark Smithers; David C Gotley
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

3.  Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.

Authors:  Yasumasa Nishimura; Ryuta Koike; Kazuhiko Ogawa; Ryuta Sasamoto; Yuji Murakami; Yoshiyuki Itoh; Yoshiharu Negoro; Satoshi Itasaka; Toru Sakayauchi; Tetsuro Tamamoto
Journal:  Int J Clin Oncol       Date:  2011-05-25       Impact factor: 3.402

4.  Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.

Authors:  M Caro; A Font; S Comas; M Viciano; J Remon; P Céliz; J Robles; E Musulén; M J Sendrós; E Mesalles; J A Jiménez; J Boix; A Arellano; J Fernández-Llamazares
Journal:  Clin Transl Oncol       Date:  2016-02-08       Impact factor: 3.405

5.  Risk factors for enlargement of cardiac silhouette on chest radiography after radiotherapy for esophageal cancer.

Authors:  Ryuta Sasamoto; Emiko Tsuchida; Tadashi Sugita; Yasuo Matsumoto; Eisuke Abe; Keisuke Sasai
Journal:  Radiat Med       Date:  2006-07

6.  Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP).

Authors:  Ryuta Sasamoto; Kunio Sakai; Hideki Inakoshi; Hiroo Sueyama; Mari Saito; Tadashi Sugita; Emiko Tsuchida; Takeshi Ito; Yasuo Matsumoto; Tadayoshi Yamanoi; Eisuke Abe; Nobuko Yamana; Keisuke Sasai
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

7.  Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.

Authors:  Baoqing Chen; Qiwen Li; Qiaoqiao Li; Bo Qiu; Mian Xi; Mengzhong Liu; Yonghong Hu; Yujia Zhu
Journal:  Oncologist       Date:  2019-12-27

8.  Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer.

Authors:  Toru Sakayauchi; Kenji Nemoto; Chikashi Ishioka; Hiroshi Onishi; Michinori Yamamoto; Tomoko Kazumoto; Masaoki Makino; Ryuji Yonekura; Jun Itami; Shigeru Sasaki; Gen Suzuki; Naofumi Hayabuchi; Hiroyasu Tamamura; Rikiya Onimaru; Tetsuo Tamamoto; Shogo Yamada
Journal:  Jpn J Radiol       Date:  2009-05-03       Impact factor: 2.374

9.  Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer.

Authors:  Mari Kogo; Ayako Suzuki; Kazuhiro Kaneko; Keiichiro Yoneyama; Michio Imawari; Yuji Kiuchi
Journal:  Dig Dis Sci       Date:  2008-02-08       Impact factor: 3.199

10.  Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).

Authors:  Masayuki Shinoda; Nobutoshi Ando; Ken Kato; Satoshi Ishikura; Hoichi Kato; Yasuhiro Tsubosa; Keiko Minashi; Hiroshi Okabe; Yusuke Kimura; Tatsuyuki Kawano; Shin-Ichi Kosugi; Yasushi Toh; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Cancer Sci       Date:  2015-03-09       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.